ESSA Pharma (EPIX) Competitors $1.86 +0.01 (+0.27%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPIX vs. DBVT, RCKT, ANNX, ABEO, IVA, GOSS, OCGN, RNAC, NGNE, and PVLAShould you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include DBV Technologies (DBVT), Rocket Pharmaceuticals (RCKT), Annexon (ANNX), Abeona Therapeutics (ABEO), Inventiva (IVA), Gossamer Bio (GOSS), Ocugen (OCGN), Cartesian Therapeutics (RNAC), Neurogene (NGNE), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. ESSA Pharma vs. Its Competitors DBV Technologies Rocket Pharmaceuticals Annexon Abeona Therapeutics Inventiva Gossamer Bio Ocugen Cartesian Therapeutics Neurogene Palvella Therapeutics ESSA Pharma (NASDAQ:EPIX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Does the media prefer EPIX or DBVT? In the previous week, ESSA Pharma had 5 more articles in the media than DBV Technologies. MarketBeat recorded 7 mentions for ESSA Pharma and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.85 beat ESSA Pharma's score of 0.42 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ESSA Pharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, EPIX or DBVT? ESSA Pharma has higher earnings, but lower revenue than DBV Technologies. ESSA Pharma is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioESSA PharmaN/AN/A-$28.54M-$0.63-2.96DBV Technologies$4.15M64.19-$113.92M-$4.92-1.98 Is EPIX or DBVT more profitable? ESSA Pharma has a net margin of 0.00% compared to DBV Technologies' net margin of -3,249.99%. ESSA Pharma's return on equity of -23.48% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets ESSA PharmaN/A -23.48% -22.86% DBV Technologies -3,249.99%-278.24%-140.54% Which has more volatility and risk, EPIX or DBVT? ESSA Pharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500. Do institutionals & insiders hold more shares of EPIX or DBVT? 75.1% of ESSA Pharma shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 15.5% of ESSA Pharma shares are held by company insiders. Comparatively, 1.4% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate EPIX or DBVT? ESSA Pharma presently has a consensus price target of $2.00, suggesting a potential upside of 7.24%. DBV Technologies has a consensus price target of $14.75, suggesting a potential upside of 51.67%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 SummaryESSA Pharma beats DBV Technologies on 9 of the 16 factors compared between the two stocks. Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPIX vs. The Competition Export to ExcelMetricESSA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.79M$2.44B$5.51B$9.39BDividend YieldN/A1.79%4.25%4.09%P/E Ratio-2.969.1928.2719.87Price / SalesN/A676.04424.8998.56Price / CashN/A160.6835.5357.53Price / Book0.664.718.215.70Net Income-$28.54M$30.99M$3.24B$257.71M7 Day Performance6.57%0.61%0.43%0.89%1 Month Performance10.36%9.70%7.84%11.09%1 Year Performance-67.28%-3.63%28.19%16.58% ESSA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPIXESSA Pharma1.0082 of 5 stars$1.87+0.3%$2.00+7.2%-66.3%$82.79MN/A-2.9650DBVTDBV Technologies3.852 of 5 stars$11.01-5.1%$14.75+34.0%+137.1%$301.56M$4.15M-2.2480RCKTRocket Pharmaceuticals4.8501 of 5 stars$2.81-3.1%$18.60+561.9%-87.8%$300.08MN/A-1.07240Trending NewsGap UpANNXAnnexon2.2237 of 5 stars$2.73-5.5%$12.50+357.9%-61.2%$299.51MN/A-2.3160ABEOAbeona Therapeutics3.739 of 5 stars$5.75-2.4%$19.25+234.8%+17.2%$294.17M$3.50M-4.5390Analyst ForecastIVAInventiva3.1733 of 5 stars$3.02+0.3%$10.40+244.4%+32.3%$288.90M$9.20M0.00100Gap DownGOSSGossamer Bio3.7831 of 5 stars$1.25+0.8%$7.33+486.7%+32.8%$284.13M$114.70M-5.43180News CoverageAnalyst ForecastGap UpOCGNOcugen1.3788 of 5 stars$0.97+1.4%$6.00+518.6%-46.7%$283.27M$4.05M-5.1180News CoveragePositive NewsRNACCartesian Therapeutics2.2345 of 5 stars$10.77-3.9%$40.67+277.6%-26.3%$279.48M$38.91M-0.2064NGNENeurogene3.4299 of 5 stars$19.50-2.9%$46.17+136.8%-50.7%$278.07M$930K-4.4890Positive NewsPVLAPalvella Therapeutics2.5187 of 5 stars$24.90+3.2%$46.29+85.9%N/A$275.29MN/A-2.06N/APositive News Related Companies and Tools Related Companies DBV Technologies Alternatives Rocket Pharmaceuticals Alternatives Annexon Alternatives Abeona Therapeutics Alternatives Inventiva Alternatives Gossamer Bio Alternatives Ocugen Alternatives Cartesian Therapeutics Alternatives Neurogene Alternatives Palvella Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPIX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPIX Stock Alerts